FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека стаков

Deep Sleep Stack

Sleep Optimizationbeginner

86

синергия

86
Share
Пептиды

2

Среднедневная дозировка мкг

200

Уровень

beginner

Добавлено

May 17, 2026

Обзор

The Deep Sleep Stack combines DSIP with low-dose Ipamorelin to create a powerful sleep-enhancement protocol that simultaneously promotes restorative sleep and maximizes the nocturnal growth hormone surge. DSIP acts on multiple neurotransmitter systems to promote slow-wave sleep initiation and maintenance. It modulates GABAergic and glutamatergic signaling, normalizes disrupted circadian cortisol rhythms, and promotes melatonin secretion from the pineal gland. Unlike pharmaceutical sleep aids that often suppress deep sleep (many benzodiazepines and Z-drugs preferentially enhance Stage 2 rather than Stage 3/4 sleep), DSIP specifically promotes the delta-wave activity that characterizes the most restorative sleep phases. Ipamorelin at the low 100mcg dose serves a dual purpose in this stack. First, GH secretagogue activity at bedtime amplifies the natural nocturnal GH pulse — the largest pulse occurs 60-90 minutes after sleep onset and is responsible for the majority of daily GH production. Second, the GH release itself promotes deeper slow-wave sleep through a positive feedback mechanism: GH-releasing neurons in the hypothalamus are interconnected with sleep-promoting neurons, creating bidirectional enhancement. The practical benefit of this combination extends beyond sleep quality: during enhanced slow-wave sleep, the glymphatic system (the brain''s waste clearance mechanism) operates at maximum efficiency, clearing metabolic byproducts and amyloid-beta that accumulate during waking hours. Growth hormone during sleep drives tissue repair, immune function, and memory consolidation. Users typically report falling asleep faster, experiencing fewer night awakenings, and waking with noticeably better energy and cognitive clarity. The protocol should be administered 30-60 minutes before intended sleep time on an empty stomach for optimal peptide absorption and GH release.

Протокол дозирования

DSIP

nightly· subcutaneous

Читать больше о DSIP →

100 mcg

на дозу

Ipamorelin

nightly· subcutaneous

Читать больше о Ipamorelin →

100 mcg

на дозу

Цели и доказательства

Deep sleepSleep qualityGH releaseRecoveryREM optimization
Уровень доказательств:Данные от человека

Предупреждения

  • DSIP timing is critical — administer 30-60 min before bed. Ipamorelin remains FDA Category 2 (restricted) as of July 2026. Do not combine with sleep medications without physician guidance.

Comments

Sign in to join the discussion

Уведомление: Этот стак представлен сообществом и предназначен для исследовательских целей только. Peptide Contacts не проверяет безопасность или эффективность представленных стаков. Всегда проконсультируйтесь с квалифицированным медицинским специалистом перед использованием любого протокола пептидов.